Subcutaneous vs Intramuscular T
The Quiet Shift in How Testosterone Is Injected
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- One testosterone enanthate auto-injector (Xyosted) is FDA-approved for subcutaneous use; other subQ use of cypionate is common but off-label by route
Reference only. Not medical advice.
What can go wrong
Subcutaneous injection of oil-based testosterone can cause local site reactions, nodules, or irritation in some men, and the cypionate-by-subQ route is off-label even though widely used. Xyosted's label carries a warning for blood-pressure increase. As with any injectable, sterile technique matters; gray-market or compounded oil and improper technique raise infection and embedded-oil risks.
This is something to take to a clinician. The Atlas can tell you what is known about subcutaneous vs intramuscular t in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Historically injectable testosterone was given deep intramuscularly with a long needle. Over the past decade practice has shifted toward subcutaneous administration with a short insulin-style needle, a change accelerated by telehealth clinics and the FDA approval of Xyosted (a subcutaneous testosterone enanthate auto-injector) in 2018. Pharmacokinetic studies show subcutaneous cypionate/enanthate achieves serum levels comparable to intramuscular dosing with good tolerability, while being far easier and less painful to self-administer. Subcutaneous, frequent, smaller dosing is also part of the practical case for flatter peaks and lower hematocrit.
The needle got shorter and shallower, and a generation of TRT patients stopped dreading injection day.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Both routes deposit an oil-based depot of testosterone ester that is slowly hydrolyzed and absorbed. Subcutaneous fat provides a slower, more even absorption surface; pharmacokinetic studies show subcutaneous testosterone cypionate and enanthate reach serum concentrations comparable to intramuscular dosing, with some evidence of a slightly smoother profile. The practical advantage is ergonomic: a short needle into abdominal or thigh fat is easier, less painful, and more reliably self-administered.
- SubQ absorption
- Slow, relatively even from fat depot
- IM absorption
- Slightly faster initial release
- Serum levels
- Comparable between routes in PK studies
- Needle
- SubQ: short insulin-style; IM: longer
Safety in detail
This intervention involves significant physiological effects and requires evaluation and monitoring by a qualified physician. Self-administration without medical oversight carries documented health risks.
What it does to fertility
Route of injection does not alter testosterone's suppression of LH/FSH and spermatogenesis; subcutaneous TRT is as fertility-suppressing as intramuscular. Fertility preservation requires gonadotropin adjuncts or a fertility-sparing alternative.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone (timed to protocol)
- Hematocrit/hemoglobin
- Blood pressure (especially with enanthate auto-injector)
- Injection-site inspection
What people get wrong
Often saidSubcutaneous testosterone doesn't absorb as well as intramuscular
ActuallyPK studies show comparable serum levels; the older 'must be deep IM' belief is not supported by the comparative data.
Often saidSubQ injection of cypionate is FDA-approved
ActuallyOnly Xyosted (enanthate auto-injector) is FDA-approved for subQ; subQ cypionate is widely used but off-label by route.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Traditional route
- Deep IM (gluteal/ventrogluteal/deltoid), longer needle
- Newer route
- SubQ, short insulin-style needle
- FDA-approved subQ product
- Xyosted (testosterone enanthate auto-injector, 2018)
- SubQ of cypionate
- Common but technically off-label by route
- Bioavailability
- Comparable serum levels in PK studies
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Subcutaneous vs Intramuscular T. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Xyosted (subcutaneous testosterone enanthate) FDA approval2018
First FDA-approved subcutaneous testosterone auto-injector; label includes a blood-pressure warning
Spratt et al. / subcutaneous testosterone PK studies (Andrology, J Urol)2017-2019
Subcutaneous dosing achieved therapeutic levels comparable to IM with good tolerability